



DuoDote[®] (atropine/pralidoxime) – Expanded indication

- On October 6, 2017, the FDA approved Meridian's DuoDote (atropine/pralidoxime) injection, for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides in adults and pediatric patients weighing more than 41 kg (90 pounds).
 - Previously, DuoDote was indicated only in adults.
 - The safety and effectiveness of DuoDote in pediatric patients < 41 kg (90 pounds) have not been established.
- The safety and effectiveness of atropine in DuoDote in patients weighing > 41 kg (90 pounds) is supported by published literature.
 - Adverse events seen in pediatric patients treated with atropine are similar to those that occur in adult patients, although central nervous system complaints are often seen earlier and at lower doses.
- The safety and effectiveness of pralidoxime chloride in DuoDote in patients > 41 kg (90 pounds) is supported by data from pharmacokinetic studies in adults and experience in the pediatric population.
- The recommended initial dosage of DuoDote for patients experiencing ≥ 2 mild symptoms is one injection intramuscularly (IM) into the mid-lateral thigh. For patients experiencing severe symptoms, three IM injections should be administered into the mid-lateral thigh in rapid succession.
 - The DuoDote autoinjector should be administered by healthcare providers who have had adequate training in the recognition and treatment of nerve agent or insecticide intoxication.
 - Consult the DuoDote drug label for explanation of mild and severe symptoms.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.